The invention is directed towards a device, method of using and making the same and more particularly to a sterile, biocompatible, fiber free, foam device configured to be used in various different uses, e.g., medical uses, make-up removal uses, and other uses.

The invention is directed towards a device, method of using and making the same and more particularly to a sterile, biocompatible, fiber free, foam device configured to be used in various different uses, e.g., medical uses, make-up removal uses, and other uses.

Wound care coverings include a pad comprising a pad material, a lactate-based enzyme crosslinked with the pad material by a crosslinker, and a dye that changes color when H.sub.2O.sub.2 is present. In examples, an enzyme layer comprises a pad material crosslinked with a sugar-based enzyme by a crosslinker, a sugar-containing layer comprises a sugar in a hydrogel, and a rupturable barrier is between the enzyme layer and sugar-containing layer. In examples, a first enzyme layer comprises a first pad material, a lactate-based enzyme and a dye that changes color when H.sub.2O.sub.2 is present; a second enzyme layer comprises a second pad material crosslinked with a sugar-based enzyme by a second crosslinker; a sugar-containing layer comprises a sugar in a hydrogel, where the second enzyme layer is between the sugar-containing layer and the first enzyme layer; and a rupturable barrier is between the second enzyme layer and the sugar-containing layer.

Wound care coverings include a pad comprising a pad material, a lactate-based enzyme crosslinked with the pad material by a crosslinker, and a dye that changes color when H.sub.2O.sub.2 is present. In examples, an enzyme layer comprises a pad material crosslinked with a sugar-based enzyme by a crosslinker, a sugar-containing layer comprises a sugar in a hydrogel, and a rupturable barrier is between the enzyme layer and sugar-containing layer. In examples, a first enzyme layer comprises a first pad material, a lactate-based enzyme and a dye that changes color when H.sub.2O.sub.2 is present; a second enzyme layer comprises a second pad material crosslinked with a sugar-based enzyme by a second crosslinker; a sugar-containing layer comprises a sugar in a hydrogel, where the second enzyme layer is between the sugar-containing layer and the first enzyme layer; and a rupturable barrier is between the second enzyme layer and the sugar-containing layer.

A medical device comprising a device that covers at least a portion of a patient's skin and has an inner surface designed to be in contact with the patient's skin. It contains a multi-ply knit fabric that contains a first knit ply and a second knit ply. The first knit ply contains a plurality of first yarns and forms the upper surface of the fabric. The second knit ply contains a plurality of polytetrafluoroethylene (PTFE) yarns which forms the lower surface of the fabric. The first and second ply are integrated through combined portions formed by interlacing first yarns among the PTFE yarns, interlacing PTFE yarns among the first yarns, and interlacing a plurality of third yarns among the first and the PTFE yarns. The multi-ply knit fabric also contains a composition comprising at least one silver ion-containing compound on at least the upper surface of the multi-ply knit fabric.

A medical device comprising a device that covers at least a portion of a patient's skin and has an inner surface designed to be in contact with the patient's skin. It contains a multi-ply knit fabric that contains a first knit ply and a second knit ply. The first knit ply contains a plurality of first yarns and forms the upper surface of the fabric. The second knit ply contains a plurality of polytetrafluoroethylene (PTFE) yarns which forms the lower surface of the fabric. The first and second ply are integrated through combined portions formed by interlacing first yarns among the PTFE yarns, interlacing PTFE yarns among the first yarns, and interlacing a plurality of third yarns among the first and the PTFE yarns. The multi-ply knit fabric also contains a composition comprising at least one silver ion-containing compound on at least the upper surface of the multi-ply knit fabric.

An equine thermal therapy overleg device that encircles a pastern of a subject horse and provides thermal therapy to the subject horse. The may include a pastern dual layer component, a distal phalanx cover and a distal phalanx slipper. The arrangement of the pastern dual layer component, a distal phalanx cover and a distal phalanx slipper allow for free movement of the subject horse and for a thermal fluid to contain ice and prevent the ice from becoming lodged around the subject horse hoof.

An equine thermal therapy overleg device that encircles a pastern of a subject horse and provides thermal therapy to the subject horse. The may include a pastern dual layer component, a distal phalanx cover and a distal phalanx slipper. The arrangement of the pastern dual layer component, a distal phalanx cover and a distal phalanx slipper allow for free movement of the subject horse and for a thermal fluid to contain ice and prevent the ice from becoming lodged around the subject horse hoof.

A breathable thermoplastic polymer film may be produced and adapted for use as a breathable diaper backsheet. The film may comprise a blend of LLDPE, mLLDPE and calcium carbonate, and may have improved tear strength and melt strength such that instances of tears or break offs during the machine direction orientation portion of the production process are significantly reduced or eliminated. In addition, the film may have sufficient tear strength to permit omission of CDI processing needed to strengthen weaker prior art films. In this regard, undesired streaking of colors or printed aspects of the film may be reduced or avoided completely.

A self-sterilizing wound dressing is disclosed. The wound dressing comprises a substrate having a first surface facing at least a portion of a wound or a surgical site and a second surface facing opposite to the first surface. At least one surface of the substrate comprises a sulfonated polymer selected from the group of perfluorosulfonic acid polymers, polystyrene sulfonates, sulfonated block copolymers, sulfonated polyolefins, sulfonated polyimides, sulfonated polyamides, sulfonated polyesters, sulfonated polysulfones, sulfonated polyketones, sulfonated poly(arylene ether), and mixtures thereof. The sulfonated polymer is sufficiently or selectively sulfonated to contain from 10-100 mol % sulfonic acid or sulfonate salt functional groups based on the number of monomer units, for killing at least 90% of microbes in less than 120 minutes of coming into contact with the wound dressing.